Plain-English translation of NCT05952453 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for newly diagnosed advanced ovarian cancer. You would receive chemotherapy drugs ( and paclitaxel) combined with an immunotherapy drug called pembrolizumab before surgery to shrink the tumor, then have surgery, and finally take maintenance medications (olaparib and pembrolizumab) afterward to help prevent the cancer from coming back.
Most ovarian cancer patients benefit from chemotherapy before surgery, but researchers want to see if adding immunotherapy upfront and continuing it after surgery can improve outcomes and help more patients stay in remission longer.
You likely qualify if…
You likely don't qualify if…
You would have a tissue biopsy before starting treatment. Then you would receive chemotherapy infusions combined with immunotherapy over several months, followed by surgery to remove as much cancer as possible. After recovery from surgery, you would continue with more chemotherapy cycles, then transition to maintenance medications (a pill and infusions) that you would take for an extended period. The study involves regular clinic visits for blood tests, scans, and monitoring, with the entire treatment lasting many months.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States